Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號 規(guī)格
Recombinant Vibrio cholerae serotype O1 Ribosomal RNA small subunit methyltransferase G (rsmG) CSB-YP399367VEY
CSB-EP399367VEY
CSB-BP399367VEY
CSB-MP399367VEY
CSB-EP399367VEY-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio cholerae serotype O1 Ribonuclease P protein component (rnpA) CSB-YP399368VEY
CSB-EP399368VEY
CSB-BP399368VEY
CSB-MP399368VEY
CSB-EP399368VEY-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio cholerae serotype O1 DNA replication and repair protein recF (recF) CSB-YP399369VEY
CSB-EP399369VEY
CSB-BP399369VEY
CSB-MP399369VEY
CSB-EP399369VEY-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio cholerae serotype O1 Coproporphyrinogen-III oxidase, aerobic (hemF) CSB-YP399370VEY
CSB-EP399370VEY
CSB-BP399370VEY
CSB-MP399370VEY
CSB-EP399370VEY-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio cholerae serotype O1 Thiazole synthase (thiG) CSB-YP399371VEY
CSB-EP399371VEY
CSB-BP399371VEY
CSB-MP399371VEY
CSB-EP399371VEY-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio cholerae serotype O1 Probable GTP-binding protein EngB (engB) CSB-YP399372VEY
CSB-EP399372VEY
CSB-BP399372VEY
CSB-MP399372VEY
CSB-EP399372VEY-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio cholerae serotype O1 Phosphoenolpyruvate carboxykinase [ATP] (pckA), partial CSB-YP399373VEY
CSB-EP399373VEY
CSB-BP399373VEY
CSB-MP399373VEY
CSB-EP399373VEY-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio cholerae serotype O1 DNA-directed RNA polymerase subunit omega (rpoZ) CSB-YP399374VEY
CSB-EP399374VEY
CSB-BP399374VEY
CSB-MP399374VEY
CSB-EP399374VEY-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio cholerae serotype O1 ATP-dependent protease subunit HslV (hslV) CSB-YP399375VEY
CSB-EP399375VEY
CSB-BP399375VEY
CSB-MP399375VEY
CSB-EP399375VEY-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio cholerae serotype O1 30S ribosomal protein S3 (rpsC) CSB-YP399376VEY
CSB-EP399376VEY
CSB-BP399376VEY
CSB-MP399376VEY
CSB-EP399376VEY-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio cholerae serotype O1 30S ribosomal protein S10 (rpsJ) CSB-YP399377VEY
CSB-EP399377VEY
CSB-BP399377VEY
CSB-MP399377VEY
CSB-EP399377VEY-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio cholerae serotype O1 50S ribosomal protein L30 (rpmD) CSB-YP399378VEY
CSB-EP399378VEY
CSB-BP399378VEY
CSB-MP399378VEY
CSB-EP399378VEY-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio cholerae serotype O1 50S ribosomal protein L17 (rplQ) CSB-YP399379VEY
CSB-EP399379VEY
CSB-BP399379VEY
CSB-MP399379VEY
CSB-EP399379VEY-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio cholerae serotype O1 Peptide methionine sulfoxide reductase MsrA (msrA) CSB-YP399380VEY
CSB-EP399380VEY
CSB-BP399380VEY
CSB-MP399380VEY
CSB-EP399380VEY-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio cholerae serotype O1 Aspartate carbamoyltransferase (pyrB) CSB-YP399381VEY
CSB-EP399381VEY
CSB-BP399381VEY
CSB-MP399381VEY
CSB-EP399381VEY-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio cholerae serotype O1 Elongation factor 4 (lepA), partial CSB-YP399382VEY
CSB-EP399382VEY
CSB-BP399382VEY
CSB-MP399382VEY
CSB-EP399382VEY-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio cholerae serotype O1 23S rRNA (uracil (1939)-C (5))-methyltransferase RlmD CSB-YP399383VEY
CSB-EP399383VEY
CSB-BP399383VEY
CSB-MP399383VEY
CSB-EP399383VEY-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio cholerae serotype O1 Phospho-N-acetylmuramoyl-pentapeptide-transferase (mraY), partial CSB-YP399384VEY
CSB-EP399384VEY
CSB-BP399384VEY
CSB-MP399384VEY
CSB-EP399384VEY-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio cholerae serotype O1 Autonomous glycyl radical cofactor (grcA) CSB-YP399385VEY
CSB-EP399385VEY
CSB-BP399385VEY
CSB-MP399385VEY
CSB-EP399385VEY-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio cholerae serotype O1 Na (+)-translocating NADH-quinone reductase subunit E, partial CSB-YP399386VEY1
CSB-EP399386VEY1
CSB-BP399386VEY1
CSB-MP399386VEY1
CSB-EP399386VEY1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長度(全長或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時,你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實驗更有可能成功。但是如果你做了錯誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗總結(jié)出了幾個有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個有用的技巧來選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://m.cstxtech.com/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點擊這里獲取更多信息。注:如果您對CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價格、交貨、質(zhì)量等,您可以點擊橙色按鈕為我們在線留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>